GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen Marseille SA (STU:IPK) » Definitions » NonCurrent Deferred Liabilities

Qiagen Marseille (STU:IPK) NonCurrent Deferred Liabilities : €0.00 Mil (As of Dec. 2014)


View and export this data going back to . Start your Free Trial

What is Qiagen Marseille NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Qiagen Marseille's non-current deferred liabilities for the quarter that ended in Dec. 2014 was €0.00 Mil.

Qiagen Marseille NonCurrent Deferred Liabilities Historical Data

The historical data trend for Qiagen Marseille's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen Marseille NonCurrent Deferred Liabilities Chart

Qiagen Marseille Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial - - - - -

Qiagen Marseille Semi-Annual Data
Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Qiagen Marseille NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Qiagen Marseille's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen Marseille Business Description

Traded in Other Exchanges
N/A
Address
Qiagen Marseille SA develops molecular diagnostic tests designed to map diseases in order to guide patients and oncologists decisions along their complex therapeutic path.

Qiagen Marseille Headlines

No Headlines